http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Shiro Nakamura ),( Hirotsugu Imaeda ),( Hiroki Nishikawa ),( Masaki Iimuro ),( Minoru Matsuura ),( Hideo Oka ),( Junsuke Oku ),( Takako Miyazaki ),( Hirohito Honda ),( Kenji Watanabe ),( Hiroshi Nak 대한장연구학회 2018 Intestinal Research Vol.16 No.4
Background/Aims: Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity in patients with IBD. However, there are the differences among several FCP assays in the dynamics of FCP. In this prospective multicenter trial, we investigated the usefulness of FCP measurements in adult Japanese patients with IBD by reliable enzyme immunoassay using a monoclonal antibody. Methods: We assessed the relationship between FCP levels and disease or endoscopic activity in patients with ulcerative colitis (UC, n=64) or Crohn’s disease (CD, n=46) compared with healthy controls (HCs, n=64). Results: FCP levels in UC patients strongly correlated with the Disease Activity Index (r<sub>s</sub>=0.676, P<0.0001) and Mayo endoscopic subscore (MES; r<sub>s</sub>=0.677, P<0.0001). FCP levels were significantly higher even in patients with inactive UC or CD compared with HCs (P=0.0068, P<0.0001). The optimal cutoff value between MES 1 and 2 exhibited higher sensitivity (94.1%). FCP levels were significantly higher in active UC patients than in inactive patients (P<0.001), except those with proctitis. The Crohn’s Disease Activity Index tended to correlate with the FCP level (rs=0.283, P=0.0565). Conclusions: Our testing method using a monoclonal antibody for FCP was well-validated and differentiated IBD patients from HCs. FCP may be a useful biomarker for objective assessment of disease activity in adult Japanese IBD patients, especially those with UC. (Intest Res 2018;16:554-562)
Shiro Masuda,Kazuya Asno 제어로봇시스템학회 2009 제어로봇시스템학회 국제학술대회 논문집 Vol.2009 No.8
This paper considers a design method for a model predictive control(MPC) approach based on a unified performance index through out the start-up phase tension and looper control which consists of the non-contact and contact modes while the looper contacts with the strip as quickly as possible. The approach employs an optimal control condition with unknown terminal time, and the terminal condition. In addition, a decoupling control during the contact mode is employed in order to suppress the deviation of the striptension. The efficiency of the proposed method is shown through a numerical simulation.
Genetics of Ossification of the Posterior Longitudinal Ligament of the Spine: A Mini Review
Shiro Ikegawa 대한골대사학회 2014 대한골대사학회지 Vol.21 No.2
Ossification of the posterior longitudinal ligament of the spine (OPLL) is a common dis-ease in aging populations and sometimes results in serious neurological problems dueto compression of the spinal cord and nerve roots. OPLL is a multi-factorial (polygenic)disease controlled by genetic and environmental factors. Studies searching for the ge-netic component of OPLL, using linkage and association analyses, are in progress andseveral susceptibility genes have been reported. This paper reviews the recent progressin the genetic study of OPLL and comments on its future task.
Shiro Masuda,Kohei Ishigaki 제어로봇시스템학회 2009 제어로봇시스템학회 국제학술대회 논문집 Vol.2009 No.8
This paper proposes a medthod for simultaneous estimation of disturbance and process gain using moving horizon estimation for discrete-time, single-input, single-output, linear time-invariant processes. The strategy for the proposed adaptive disturbance estimator is to minimize a moving-horizon performance index which consist of quadratic forms of estimated output error and disturbances. Furthermore, we propose a recalculation method using two patterns of estimated values of disturbance and process gain for different two input signals. Through a numerical simulation for the approximated process model of an oxygen converter gas recovery process, the efficiency of the proposed method will be shown.
Shiro Nakamura,Teita Asano,Hiroaki Tsuchiya,Kanami Sugimoto,Yuya Imai,Seiji Yokoyama,Yasuo Suzuki 대한장연구학회 2022 Intestinal Research Vol.20 No.3
Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.Methods: Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.Results: Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population.Conclusions: The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.